James Waldron

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in series A funds to push forward its potential Keytruda contender.

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million up front to help bypass the blood-brain barrier.

A pair of Regeneron's monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial , with one of the candidates also matching Bristol Myers Squibb and Pfizer's Eliquis.

KdT Ventures has signed off on a $608 million biobucks dea l for NGM Biopharmaceuticals' phase 2-ready metabolic-dysfunction associated steatohepatitis (MASH) drug, with the VC firm setting up a new company to house the therapy.

Idorsia's plans to sell its hypertension drug Tryvio have faced a speedbump , even as the biotech ploughs ahead with around 250 layoffs.

The failure of a myeloid leukemia drug in a phase 3 trial in China isn't a shock to Apollomics, which had already given up on the E-selectin inhibitor.

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news hasn't let up since.

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook.

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3.

After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a sustainable path forward via a merger into privately owned immunology company Inmagene Biopharmaceuticals.